AnteMEL - cancer risk test

Genetic test that determines the polygenic risk score and assesses the individual's risk of developing melanoma.

This is a next-generation test based on genetics and statistical sciences data. The genetic analysis team provides a detailed interpretation of the test results, indicating identified mutations (single nucleotide polymorphisms, SNP) and, by summing the effects of risk-increasing and risk-decreasing mutations, provides an estimate of the polygenic risk of developing the type of cancer being tested. The patient's risk is compared with the average risk of patients in their age group, thus overcoming the gaps of conventional health screening programs that are based solely on the patient's age without considering individual risk factors. The test result report includes medical recommendations: specifies the necessary frequency of specialized screening, recommended cancer risk reduction methods, including the use of individualized preparations.

The AnteMEL test is one of the tools for early prevention and early detection of melanoma. The goal of this test is to reduce the risk of early mortality from melanoma by applying primary and secondary prevention measures.

Recommendation from when to perform the test: recommended for women and men aged 18-70 years.

Sample: oral mucosa swab.

Execution time after entering the laboratory: 3 - 6 weeks.